Heron Therapeutics is trading 13.53% down at $0.42 after second-quarter 2026 revenue missed expectations at $37.7 million versus the $42.19 million consensus estimate.
- Management withdrew full-year 2026 financial guidance, citing uncertainty around generic competition for its lead product and exploration of strategic alternatives.
- The results conference call is scheduled for 8:30 a.m. EDT on August 10, 2026.